A Phase 1 study of RiMO-301, Radiotherapy, and PD-1 Inhibitor in Head-Neck Cancer
Recruiting Phase 1,Phase 2 NCT05838729
Study Description
A Study of a New Immunotherapy Combination for Advanced Head and Neck Cancer
Study Details
- Registry ID:
- NCT05838729
- Conditions:
- Head Neck Cancer, Intratumoral Injection
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 16 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Illinois at Chicago
Chicago, Illinois, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.